AI and policy reform set to reshape UK drug development
BCG’s Chris Meier outlines how advances in AI and new…
BCG’s Chris Meier outlines how advances in AI and new UK policies could accelerate drug development, streamline clinical trials and strengthen the country’s life sciences sector.




